Cargando…

Recent advances in genetic modification of adenovirus vectors for cancer treatment

Adenoviruses are widely used to deliver genes to a variety of cell types and have been used in a number of clinical trials for gene therapy and oncolytic virotherapy. However, several concerns must be addressed for the clinical use of adenovirus vectors. Selective delivery of a therapeutic gene by a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Yuki, Nagasato, Masaki, Yoshida, Teruhiko, Aoki, Kazunori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448613/
https://www.ncbi.nlm.nih.gov/pubmed/28266780
http://dx.doi.org/10.1111/cas.13228
_version_ 1783239587101933568
author Yamamoto, Yuki
Nagasato, Masaki
Yoshida, Teruhiko
Aoki, Kazunori
author_facet Yamamoto, Yuki
Nagasato, Masaki
Yoshida, Teruhiko
Aoki, Kazunori
author_sort Yamamoto, Yuki
collection PubMed
description Adenoviruses are widely used to deliver genes to a variety of cell types and have been used in a number of clinical trials for gene therapy and oncolytic virotherapy. However, several concerns must be addressed for the clinical use of adenovirus vectors. Selective delivery of a therapeutic gene by adenovirus vectors to target cancer is precluded by the widespread distribution of the primary cellular receptors. The systemic administration of adenoviruses results in hepatic tropism independent of the primary receptors. Adenoviruses induce strong innate and acquired immunity in vivo. Furthermore, several modifications to these vectors are necessary to enhance their oncolytic activity and ensure patient safety. As such, the adenovirus genome has been engineered to overcome these problems. The first part of the present review outlines recent progress in the genetic modification of adenovirus vectors for cancer treatment. In addition, several groups have recently developed cancer‐targeting adenovirus vectors by using libraries that display random peptides on a fiber knob. Pancreatic cancer‐targeting sequences have been isolated, and these oncolytic vectors have been shown by our group to be associated with a higher gene transduction efficiency and more potent oncolytic activity in cell lines, murine models, and surgical specimens of pancreatic cancer. In the second part of this review, we explain that combining cancer‐targeting strategies can be a promising approach to increase the clinical usefulness of oncolytic adenovirus vectors.
format Online
Article
Text
id pubmed-5448613
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-54486132017-06-01 Recent advances in genetic modification of adenovirus vectors for cancer treatment Yamamoto, Yuki Nagasato, Masaki Yoshida, Teruhiko Aoki, Kazunori Cancer Sci Review Articles Adenoviruses are widely used to deliver genes to a variety of cell types and have been used in a number of clinical trials for gene therapy and oncolytic virotherapy. However, several concerns must be addressed for the clinical use of adenovirus vectors. Selective delivery of a therapeutic gene by adenovirus vectors to target cancer is precluded by the widespread distribution of the primary cellular receptors. The systemic administration of adenoviruses results in hepatic tropism independent of the primary receptors. Adenoviruses induce strong innate and acquired immunity in vivo. Furthermore, several modifications to these vectors are necessary to enhance their oncolytic activity and ensure patient safety. As such, the adenovirus genome has been engineered to overcome these problems. The first part of the present review outlines recent progress in the genetic modification of adenovirus vectors for cancer treatment. In addition, several groups have recently developed cancer‐targeting adenovirus vectors by using libraries that display random peptides on a fiber knob. Pancreatic cancer‐targeting sequences have been isolated, and these oncolytic vectors have been shown by our group to be associated with a higher gene transduction efficiency and more potent oncolytic activity in cell lines, murine models, and surgical specimens of pancreatic cancer. In the second part of this review, we explain that combining cancer‐targeting strategies can be a promising approach to increase the clinical usefulness of oncolytic adenovirus vectors. John Wiley and Sons Inc. 2017-05-07 2017-05 /pmc/articles/PMC5448613/ /pubmed/28266780 http://dx.doi.org/10.1111/cas.13228 Text en © 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Review Articles
Yamamoto, Yuki
Nagasato, Masaki
Yoshida, Teruhiko
Aoki, Kazunori
Recent advances in genetic modification of adenovirus vectors for cancer treatment
title Recent advances in genetic modification of adenovirus vectors for cancer treatment
title_full Recent advances in genetic modification of adenovirus vectors for cancer treatment
title_fullStr Recent advances in genetic modification of adenovirus vectors for cancer treatment
title_full_unstemmed Recent advances in genetic modification of adenovirus vectors for cancer treatment
title_short Recent advances in genetic modification of adenovirus vectors for cancer treatment
title_sort recent advances in genetic modification of adenovirus vectors for cancer treatment
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448613/
https://www.ncbi.nlm.nih.gov/pubmed/28266780
http://dx.doi.org/10.1111/cas.13228
work_keys_str_mv AT yamamotoyuki recentadvancesingeneticmodificationofadenovirusvectorsforcancertreatment
AT nagasatomasaki recentadvancesingeneticmodificationofadenovirusvectorsforcancertreatment
AT yoshidateruhiko recentadvancesingeneticmodificationofadenovirusvectorsforcancertreatment
AT aokikazunori recentadvancesingeneticmodificationofadenovirusvectorsforcancertreatment